DE10155841A1 - MCH-Rezeptor interagierendes Zinkfinger-Protein - Google Patents
MCH-Rezeptor interagierendes Zinkfinger-ProteinInfo
- Publication number
- DE10155841A1 DE10155841A1 DE2001155841 DE10155841A DE10155841A1 DE 10155841 A1 DE10155841 A1 DE 10155841A1 DE 2001155841 DE2001155841 DE 2001155841 DE 10155841 A DE10155841 A DE 10155841A DE 10155841 A1 DE10155841 A1 DE 10155841A1
- Authority
- DE
- Germany
- Prior art keywords
- protein
- mch
- polynucleotide
- mizip
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 title claims abstract description 101
- 101710185494 Zinc finger protein Proteins 0.000 title description 3
- 102100023597 Zinc finger protein 816 Human genes 0.000 title description 3
- 102000006953 melanin-concentrating hormone receptor activity proteins Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 140
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 110
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 claims abstract description 100
- 239000012634 fragment Substances 0.000 claims abstract description 53
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 46
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 46
- 239000002157 polynucleotide Substances 0.000 claims abstract description 46
- 241000282414 Homo sapiens Species 0.000 claims description 74
- 210000004027 cell Anatomy 0.000 claims description 40
- 150000001413 amino acids Chemical group 0.000 claims description 33
- 230000014509 gene expression Effects 0.000 claims description 32
- 102000037865 fusion proteins Human genes 0.000 claims description 30
- 108020001507 fusion proteins Proteins 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- 230000003993 interaction Effects 0.000 claims description 19
- 238000009396 hybridization Methods 0.000 claims description 18
- 239000012472 biological sample Substances 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 13
- 230000009261 transgenic effect Effects 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000036528 appetite Effects 0.000 claims description 8
- 235000019789 appetite Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 229930193140 Neomycin Natural products 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 229960004927 neomycin Drugs 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 238000011835 investigation Methods 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 230000003893 regulation of appetite Effects 0.000 claims description 3
- 238000012827 research and development Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 210000004898 n-terminal fragment Anatomy 0.000 claims description 2
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 108091008039 hormone receptors Proteins 0.000 claims 1
- 230000012743 protein tagging Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- 102000003839 Human Proteins Human genes 0.000 abstract 1
- 108090000144 Human Proteins Proteins 0.000 abstract 1
- 101000788675 Homo sapiens Zinc finger MYND domain-containing protein 19 Proteins 0.000 description 127
- 102100025103 Zinc finger MYND domain-containing protein 19 Human genes 0.000 description 96
- 235000018102 proteins Nutrition 0.000 description 70
- 241001529936 Murinae Species 0.000 description 52
- 102000054654 human ZMYND19 Human genes 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 14
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 13
- HNDVDQJCIGZPNO-UHFFFAOYSA-N Histidine Chemical compound OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 102000005720 Glutathione transferase Human genes 0.000 description 11
- 108010070675 Glutathione transferase Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 102000016267 Leptin Human genes 0.000 description 10
- 108010092277 Leptin Proteins 0.000 description 10
- 230000006399 behavior Effects 0.000 description 10
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 229940039781 leptin Drugs 0.000 description 10
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 8
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 8
- 101710151321 Melanostatin Proteins 0.000 description 7
- 102400000064 Neuropeptide Y Human genes 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 7
- 210000001550 testis Anatomy 0.000 description 7
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 210000001638 cerebellum Anatomy 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 238000010379 pull-down assay Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 201000008645 Joubert syndrome Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003796 lateral hypothalamic area Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 238000011895 specific detection Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 101100353517 Caenorhabditis elegans pas-2 gene Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 241001635598 Enicostema Species 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010027626 Milia Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 210000004727 amygdala Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000013115 immunohistochemical detection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000001956 orexigenic effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- YYYARFHFWYKNLF-UHFFFAOYSA-N 4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=C12 YYYARFHFWYKNLF-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- -1 LacZ pneo Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101150106280 Mchr1 gene Proteins 0.000 description 1
- 108700036626 Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100160974 Mus musculus Zmynd19 gene Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- KMNTUASVUKNVJS-UHFFFAOYSA-N Ponceau S (acid form) Chemical compound OC1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C=CC2=C1N=NC(C(=C1)S(O)(=O)=O)=CC=C1N=NC1=CC=C(S(O)(=O)=O)C=C1 KMNTUASVUKNVJS-UHFFFAOYSA-N 0.000 description 1
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 101000581407 Rattus norvegicus Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002891 anorexigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001042 autoregulative effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015289 cerebelloparenchymal disease Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 101150024647 mch gene Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000027272 reproductive process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001155841 DE10155841A1 (de) | 2001-11-14 | 2001-11-14 | MCH-Rezeptor interagierendes Zinkfinger-Protein |
| PCT/EP2002/012714 WO2003042242A1 (fr) | 2001-11-14 | 2002-11-13 | Proteine a doigts de zinc interagissant avec le recepteur de la mch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001155841 DE10155841A1 (de) | 2001-11-14 | 2001-11-14 | MCH-Rezeptor interagierendes Zinkfinger-Protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10155841A1 true DE10155841A1 (de) | 2003-05-28 |
Family
ID=7705676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2001155841 Withdrawn DE10155841A1 (de) | 2001-11-14 | 2001-11-14 | MCH-Rezeptor interagierendes Zinkfinger-Protein |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE10155841A1 (fr) |
| WO (1) | WO2003042242A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040034996A (ko) * | 2002-10-18 | 2004-04-29 | 한미약품 주식회사 | 리스페리돈의 개선된 제조방법 |
-
2001
- 2001-11-14 DE DE2001155841 patent/DE10155841A1/de not_active Withdrawn
-
2002
- 2002-11-13 WO PCT/EP2002/012714 patent/WO2003042242A1/fr not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| Internet-Recherche am 22.01.2003 http://www.ncbi. nlm.nih.gov/entrez Accession Number BC012948 22-Aug-2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003042242A1 (fr) | 2003-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL185549B1 (pl) | Wyizolowany kwas nukleinowy, sposób identyfikowania wariantów allelicznych ludzkiego genu prezeniliny, komórka gospodarza, modelowe zwierzę, sposób wytwarzania domeny funkcjonalnej prezeniliny, zasadniczo czyste białko, zasadniczo czysty preparat białka, zasadniczo czysty polipeptyd, zasadniczo czysty preparat polipeptydu, zasadniczo czysty preparat przeciwciała, sposób wytwarzania przeciwciał, linia komórkowa, sposób identyfikowania związków, sposoby diagnozowania, kompozycja farmaceutyczna, zastosowanie wektora ekspresyjnego, rekombinowany wektor, zwierzę transgeniczne | |
| DE69738637T2 (de) | Leptinrezeptor db, den rezeptor kodierende nukleinsäuren und anwendungen desselben | |
| SK22197A3 (en) | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof | |
| DE69417223T2 (de) | Ein menschlicher t-zell rezeptor der protein g-gekoppelte rezeptor familie | |
| DE69825629T2 (de) | Säugertier edg-7 rezeptor homologen | |
| DE60036548T2 (de) | Neue kalium-kanäle und dafür kodierende gene | |
| JP2002523094A (ja) | アタキシン−２結合タンパク質をコードする核酸、それらに関する産物、およびそれらを使用する方法 | |
| US8273548B2 (en) | Nucleic acids encoding a human PAP1 polypeptide | |
| JPH06211898A (ja) | 神経α−カテニン | |
| CH694588A5 (de) | Menschliche intestinale Npt2B. | |
| US7294710B2 (en) | High-affinity choline transporter | |
| DE10155841A1 (de) | MCH-Rezeptor interagierendes Zinkfinger-Protein | |
| JPH11235186A (ja) | 神経組織のナトリウムチャンネルをコードする核酸 | |
| US20040053812A1 (en) | Methods | |
| US20040093627A1 (en) | Methods | |
| US20040072220A1 (en) | Neurotonin and use thereof | |
| DE60024862T2 (de) | "insulinabhängiges sequenz dna bindendes protein-1" (irsdbp-1), dafür kodierendes gen und ihre verwendungen | |
| US20060116505A1 (en) | Glucose and/or fructose transporter naglt1 and its gene | |
| US6365126B1 (en) | Learning and short term memory defects with Neurofibromatosis 1 (NF1) expression | |
| JP2005522179A (ja) | 精製および単離されたカリウム−クロライド共輸送体核酸およびポリペプチドならびにそれらを用いる治療およびスクリーニング法 | |
| DE60127988T2 (de) | Modifizierungsmittel des organell-stoffwechsels | |
| AU2006235783B8 (en) | Compositions useful for regulating parkin gene activity | |
| WO2001036634A1 (fr) | Nouveaux recepteurs couples a la proteine g, genes desdits recepteurs et leur utilisation | |
| US20050250720A1 (en) | Novel compound | |
| AT410945B (de) | Verfahren zur diagnose von multipler sklerose (ms) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8181 | Inventor (new situation) |
Inventor name: B?CHNER, DIETMAR, 22529 HAMBURG, DE Inventor name: KREIENKAMP, HANS-JUERGEN, 22391 HAMBURG, DE Inventor name: RICHTER, DIETMAR, 22529 HAMBURG, DE |
|
| 8139 | Disposal/non-payment of the annual fee |